| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | A1:E4 | Updated 5/1/2024 | The Americas, Europe, China, Other Asia/Africa, Australia | |||||||||||||||||||||||
2 | Date | Trial Summary | Phase | Inclusion Criteria | Locations | Sponsors | Identifier- LINK | Comments | ||||||||||||||||||
3 | Studies Recruiting for Surgically Resectable Disease - ALK NSCLC Stage 1A to IIIA | |||||||||||||||||||||||||
4 | 2/1/2023 | Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC (VIGOR) | 4 | IIB to IIIA adenocarcinoma of the lung (includes ALK) Lesion size less than or equal to 5 cm Participant is candidate for definitive surgical resection No cancer therapy 2 for years prior Can not require pneumonectory | USA: Rochester MN, Philadelphia PA | Galvanize therapeutics | NCT05583188 | Aliya is a Pulsed Electric Fields device. This PEF device can ablate lung tissue though a small incision into the skin or broncoscopy. Biopsies can also be obtained. Surgery and chemotherapy per establisehd protocols will follow the PEF ablation. The hope is that PEF ablation will make surgery and subsequent therapies more successful | ||||||||||||||||||
5 | 5/20/2021 | Alectinib before surgery (Neo-adjuvant) in stage III ALK Positive NSCLC (ALNEO) | 2 | Locally advanced stage 3 ALK+ adenocarcinoma of the lung Mixed histology okay if adenocarcinoma is prominent Candidate for surgical resection No prior systemic treatment for lung cancer | Italy: Aviano, Bari, Bologna, Catania, Firenze, Genova,Lido De Camaiore. Meldola, Modela, Monza, Napoli, Obassano, Padova, Parma, Perugia, Roma, Rozzano. Verona. | Gruppo Oncologico Italiano di Ricerca Clinica | NCT05015010 | Alectinib will be adminstered 8 weeks before surgery. After surgery, alectinib will continue up to 96 weeks. | ||||||||||||||||||
6 | 7/31/2020 | Alectinib, (Entrectinib, or Vemurafenib Plus Cobimetinib) in Resectable Stages IB-III NSCLC with ALK,(ROS-1, NTRK or BRAFv600E) Molecular Alterations (NAUTIKA-1) (Stages IA2 - IIIAB) | 2 | Resectable stage 1A2, 1B, 2, 3A or selected 3B ALK+ NSCLC Will receive up to 8 weeks Alectinib before surgical resection and/or radiotherapy as recommended by treating physician | USA: LA, Orange, Sacramento, San Francisco, CA; Denver CO, New Haven CT,Tampa FL, Chicago IL, Boston MA, Ann Arbor, MI: Columbia, St Louis, MO; Lebanon NH, NY, NY; Columbus OH, Pittsburgh PA, Memphis TN, Houston, Kingwood, TX, Washington DC, Fairfax, VA. | Genentech | NCT04302025 | Innovative in that tumors will be reduced with Alectinib before resection. May also be possible to continue Alectinib after surgery/radiation. | ||||||||||||||||||
7 | 8/18/2014 | Crizotininb in patients with IB-IIIA ALK NSCLC that has been removed by surgery (An ALCHEMIST Treatment Trial) | 3 | Stage IB, II, or non-squamous IIIA , ALK NSCLC - NED Complete resection of tumors with negative margins No prior treatment with ALK TKI Surgery 4 weeks to 300 days prior (depends on situation) Adjuvant radiation or chemo okay | USA: 1498 sites | ECOG-ACRIN Reserach National Cancer Institute | NCT02201992 | Randomized to Crizotinib up to 2 years vs observation without Criz | ||||||||||||||||||
8 | Studies Recruiting for Stage II-III Unresectable Disease - ALK NSCLC | |||||||||||||||||||||||||
9 | 5/1/2023 | Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer (BOUNCE) (Brigatinib vs. durvalumab or observation) | 2 | Newly diagnosed, Stage III unresectable ALK+ NSCLC, Completed chemo-radiotherapy withour progression No prior treatment | France: Angers, Caen, Italy: Novara Spain: Alicante, Bilbao More sites in France, Italy, Poland, UK planned | ETOP IBCSG Partners Takeda | NCT05718297 | Particiapants will be randomized to brigatinib 180 mg per day, or observation/durvalumab after completing chemoradiation without progression. Durvalumab is optional per investigators choice. Drugs like durvalumab have not been effective for ALK in other studies, and durvalumab may cause harm. A participant should only choose durvalumab if they have done their own research on risks and benefits, in addition to the information given by their oncologists. | ||||||||||||||||||
10 | 7/15/2022 | Alectinib vs durvalumab: A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) | 3 | Newly diagnosed, Stage III unresectable ALK+ NSCLC, Prior receipt of at least 2 cycles of platinum-based chemotherapy Prior radiation okay (ROS1 or RET mutations included with their assocated TKIs) | USA, Australia, Belgium, Brazil, Canada, Chile, China, Columbia, Costa Rica, France, Germany, Hong Kong, Israel, Italy, Japan, Korea, Norway, Poland, Serbia, Spain, Sweden Singapore, Taiwan, Thailand, Turkey, UK, New Zealand | Hoffmann-La Roche | NCT05170204 | Particiapants will be randomized to receive either alectinib or durvalumab after chemotherapy.Durvalumab is an checkpoint inhibitor immunotherapy, and this class of drug is usually not effective in later stages of ALK lung cancer. Based on current research, alectinib is likely to be far more effective than durvalumab. Anyone entering this trial should have an excellent understanding of risks and benefits, preferably beyond what they are told by their oncologist. | ||||||||||||||||||
11 | 9/13/20219 | Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer | 1 | Stage II or III unresectable ALK+ NSCLC, including ALK Deemed to be best treated by radiotherapy No prior lung cancer treatment for stage II or III | USA: Houston, Texas (MD Anderson) | MD Anderson National Cancer Institute | NCT04013542 | It is specifically mentioned that ALK is eligble for this trial. | ||||||||||||||||||
12 | Recruiting for 1st Line ALK Inhibitor Stage IIIB to IV (No Prior ALK TKI Treatment) | |||||||||||||||||||||||||
13 | 9/2023 | Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements (DURABLE) (Alectinib + SRS) | 1/2 | Stage 4 ALK NSCLC Must have 1-15 intrcranial metastases less than 3 cm with only one lesion more than 2 cm Minimally symptomatic or asymptomatic brain mets with no plan for surgery within 28 days Okay if symptoms are controlled with steroids or anti-sseizure meds No prior ALK TKIs or other cancer treatment since diagnosed with stage 4 | USA: Columbus, Ohio | Joshua Palmer Genetech | NCT05987644 | Participants will receive radiation therapy to brain mets prior to starting alectinib | ||||||||||||||||||
14 | 10/5/2023 | Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB) | NA | Stage IIIB, IV or recurrent ALK NSCLC Stable disease or partial response after 2-3 month on alectinib Maximum 5 tumor lesions + throacic lymph nodes No LMD No progression after 2-3 months alectinib | Sweden: Stockholm | Karolinska University Hospital | NCT05724004 | Participants will receive radiation to tumors after the tumors have been shrunk with alectinib | ||||||||||||||||||
15 | 10/15/2022 | Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer (USZ-STRIKE) | III | Newly diagnosed ALK NSCLC with brain metastases Mild symptoms from brain met(s), requiring no more than 4 mg dexamethasone. Prior surgery for brain mets allowed No previous treatment for lung cancer except brain surgery for mets No previous radiation for brain mets | Italy: Siena, Perugia, (Sites planned in Napoli, Roma) Netherlands: Amsterdam Switzerland: Bern, Zurich,Winterthur UK: (Sites planned in Sutton, Manchester) | ETOP IBCSG Partners Foundation USZ Foundation | NCT05522660 | Participants will be randomized to receive ALK inhibitor alone vs. SRS brain radiation before ALK inhibitor. | ||||||||||||||||||
16 | 5/18/2022 | Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK) | 2 | Advanced ALK+ NSCLC, not eligible for local treatment TKI naïve Brain mets must be stable At least 12 months since chomtherapy for earlier stage lung cancer | France: 32 sites | Intergroupe Francophone de Cancerologie Thoracique | NCT05200481 | Participants with no previous TKI use will be randomized to receive either brigatinib plus 4 cycles of carbo/pemetrexed chemotherapy or brigatinib alone. | ||||||||||||||||||
17 | 5/1/2022 | Alectinib Pharmacokinetic in Patients With NSCLC | 1/2 | Advanced or recurrent or metastatic ALK+ NSCLC TKI naïve Brain mets okay if stable: no LMD | Mexico: Mexico City | Insittuto Nacional de Cancerologia de Mexico | NCT05713006 | Participants will be given alectinib at escalating doses and blood levels will be obtained. Alectinib dosing will be based on these blood levels | ||||||||||||||||||
18 | 3/23/2022 | Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels (ADAPT ALEC) | 4 | Advanced or recurrent or metastatic ALK+ NSCLC TKI naïve One previous line of chemotherapy okay Brain mets or LMD okay if stable | Netherlands: Amsterdam, Leiden, Rotterdam, Groningnen, Maastrich. More sites in Netherlands and France planned. | Various University and Cancer Center sponsors in Netherlands | NCT05525338 | Randomized to standard dose alectnib vs dose adjustments based on blood levels of the drug. | ||||||||||||||||||
19 | 10/1/2019 | OMEGA, A Randomized Trial of Local Ablative Therapy Vs. Conventional Treatment in Oligometastatic NSCLC | 3 | Advanced or metastatic ALK+ NSCLC No previous systemic treatment (may consider if started systemic treatment 3 months before without progression) Primary tumor amenable to surgery or radiation Between 1-3 metastatic lesions | Italy: Verona | Azienda Ospedaliera Universitaria Integrata | NCT03827577 | Randomized to ALK TKI vs Local Ablative Therapy (radation or surgery) to all metastatic sites, with ALK TKI | ||||||||||||||||||
20 | Recruiting for 1st or 2nd+ Line Treatment (ALK TKI Treatment Naïve or Prior ALK TKIs) | |||||||||||||||||||||||||
21 | ||||||||||||||||||||||||||
22 | 5/3/2023 | Patient-centered, Optimal Integration of Survivorship and Palliative Care (POISE) (Palliative Care Intervention at Diagnosis) | NA | Age 18 or older MGH Cancer Center patient Within 6 months of diagnosis of metastatic ALK NSCLC Receiving targeted therapy Ability to respond in English or Spanish | USA: Boston, Mass General | Mass General Americal Lung Association | NCT04900935 | Patents will receive four 60 minute visits with a palliative care physician who is trained to address the psychosoical issues and health promoting behaviors of people with long, uncertain cancer trajectories. | ||||||||||||||||||
23 | 8/17/2023 | Lorlatinib in Combination With Ramucirumab in People With Lung Cancer | 1/2 | Metastatic or recurrent ALK lung cancer ALK treatment naïve OR progression or intolelrance of at least one second gen ALK TKI (alectninb, ceritinb, brigatinib) Prior chemo okay No prior lorlatinib or ramuciramab No active brain mets | USA: Middletown NJ, Montvale NJ, Comack, Harrison, NYNY, Rockville Centre NY | Sloan Kettering Cancer Center Eli Lilly and Co | NCT06007937 | Participants will receive the combination or lorlatinib and ramuciramab. Ramuciramab is an angiogenesis inhibitor targeting VEGR. It limits blood supply to the cancer to limit growth. Ramuciramab is in the same drug category as Avastin (bevacizumab), but it may cause fewer side effects. | ||||||||||||||||||
24 | 7/21/2022 | Multi-modality local consolidative treatment (LCT) versus conventional care of advanced lung cancer after first line systemic anti-cancer treatment (RAMON) | 3 | Stage 4 ALK lung cancer (or other types) Currently prescribed TKI for a minimum of 3 months Able to have local treatment to all areas of residual disease | UK: London (Royal Brompton). Other sites in the UK planned. | NIHR | https://fundingawards.nihr.ac.uk/award/NIHR131306 | Participants will be randomzed to have either LCT after starting a TKI, vs. TKI and standard treatment only. | ||||||||||||||||||
25 | 4/1/2022 | Exercise in Extended Oncogene Addicted Lung Cancer In Active Treatment (EXcellenT) | N/A | ALK NSCLC on first or second line systemic treatment (TKI) Not suitable for local treatment Prior radiotherapy and chemotherapy allowed | Italy: Ravenna | AUSL Romagna Rimini Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | NCT05306652 | Patients will be randomized to receive supervised physical activity vs. unsupervised physical acitivity. Qualiy of life and overall survival will be measured between the two groups. | *** | |||||||||||||||||
26 | 12/10/2021 | Personalized Dendritic Cell Vaccines in NSCLC (ALK included) | 1 | Advanced ALK NSCLC stage IV or unresectable stage III On standard of care treatment with crizotinib, alectinib,or lorlatinib No progression on current treatment | Switzerland: Lausanne | Centre Hospitalier Universitaire Vaudois | NCT05195619 | Six doses of personalized dendritic cell vaccine will be added to standard of care ALK inhibitor treatment | ||||||||||||||||||
27 | 11/10/2020 | Observation or Upfront Cranial Radiation in Oncogene Driver Mutated NSCLC With Asymptomatic Brain Metastases (including ALK) | 3 | ALK or EGFR lung cancer Asymptomatic brain metastases No previous brain radiation No brain stem metastases | India: Mumbai, Tata Memorial Hospital | Tata Memorial Hospital | NCT05236946 | Patients with brain metastases will be randomized to receive brain radiation (SRS or WBR) before ALK-TKI, or ALK-TKI alone | ||||||||||||||||||
28 | 11/11/2019 | TKI Alone Versus TKI and Local Consolidative Radiation Therapy in ALK (or other oncogene) NSCLC (TARGET-01) | 2 | Oncogene driver NSCLC At least 2-4 months of TKI treatment without progression 1-5 sites of metastatic disease not including primary tumor and regional nodes No prior radiation to thorax | India: Mumbai, Tata Memoral Hospital | Tata Memorial Hospital | NCT05277844 | Participants will be randomized to receive radiation local consolidative therpy with TKI vs. TKI alone | ||||||||||||||||||
29 | 9/14/2017 | Alectinib combined with Cobimetinib (MEK inhibitor) in advanced ALK NSCLC | 1B/2 | ALK stage IV Treatment naïve or previously treated with ALK TKIs or chemo Brain mets must be treated if progresssed on Alectinib | USA: Boston - Mass General | Mass General Genentech | NCT03202940 | |||||||||||||||||||
30 | 12/2016 | Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer (STARTNEWERA-OM) | N/A | Oligometastatic NSCLC (ALK included), either at diagnosis or progression Ability to safely treat target lesions with raidation Brain mets must be stable | Italy:Terni | Radiotherapy Onconogy Centre S. Maria Hospital | NCT06207292 | Targeted radiation will be applied to residual or progressive tumors while ALK TKI therapy is maintained | ||||||||||||||||||
31 | 10/7/2016 | Lorlatinib with brain mets and/or LMD in the absence of measurable lesions outside the brain | 2 | Treatment naïve or previous ALK TKIs or chemo LMD or at least one brain met 5 mm or larger No measurable disease outside brain or nervous system | USA: Boston - Mass General | Mass General | NCT02927340 | |||||||||||||||||||
32 | Recruiting for ALK NSCLC 2nd-3rd-4th Line Treatment After One or More ALK TKIs | |||||||||||||||||||||||||
33 | 8/24/2024 | Prophylactic Neopeptide Vaccine in Advanced ALK+ NSCLC | 1/2 | Advanced ALK lung cancer Must be suitable for biopsy Must be able to stop other cancer therapies | USA: Baltimore MD (Johns Hopkins) | Sidney Kimmel Cancer Center at Johns Hopkins | NCT05950139 | Participants will receive radiation therapy to all known tumor lesions after 2-3 months treatment with alectinib | ||||||||||||||||||
34 | 5/2024 | Gilteritinib for the Treatment of ALK NSCLC | 1 | Stage IV ALK NSCLC Adeoncarcinoma, squamous, adenosquamous included Progression on at least one TKI Prior chemo, immunotherapy, and other cancer agents okay Brain mets must be stable | USA: Ann Arbor MI | UM Rogel Cancer Center | NCT06225427 | Giltertinib is an ALK inhibitor which also inhibits other cancer metabolic pathways. It is already approved for treatment in leukemia. | ||||||||||||||||||
35 | 3/15/2024 | Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib (ALK-PPL) | 2 | Confirmed diagnosis of stage IV ALK positive NSCLC Progression outside of brain on Lorlatinib Lorlatinib may be in first- or further-line No limit on prior therapies No brain progression | Italy: Aviano. Sites planed in Firenze, Lido Di Camaiore, Meldola, Monza, Padova, Parma, Perugia, Udine | Centro di Riferimento Oncologico - Aviano | NCT06378892 | |||||||||||||||||||
36 | 11/12/2023 | MK-2870 Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) | 3 | Lung Adenocarcinoma ALK-Rearranged Stage IIIA-IV Progression after last treatment 1-2 prior lines of EGFR-TKI and prior platinum chemotherapy (Maybe prior ALK-TKI will be accepted) | USA: Orange City FL, Marietta GA, Hattiesburg MS, Pennington NJ Australia: Westmead,NewSouth Wales. Clayton, Melbourne. Canada: Brampton Chile: Talca, Santiago, Valparaiso Hong Kong: Central, Hksar, Kowloon, Lai Chi Kok Korea: Seoul, Hwason, Goyand-si, Busan, Israel: Haifa, Jerusalem, Petah Tikva. Malaysia: Kuala Lampur Taiwan: Hsinchu, Kaohsiung, Tainan, Taipei, Changhua, Kaohsiung, Tainan. | Merck Sharp & Dohme LLC | NCT06074588 | MK-2870 is an anti-TROP antibody-drug conjugate. Participants will be randomly assigned to MK-2870 or chemotherapy . The study design seems entirely based on EGFR lung cancer. Although ALK is mentioned in the study design, it's not clear ALK will be accepted. | ||||||||||||||||||
37 | 8/8/2023 | Amivantamab With Tyrosine Kinase Inhibitor (TKI) | 1/2 | Stage III unresectable or stage IV ALK Known ALK, ROS1 or RET fusion Progression on at least one TKI, on the same dose for at least 3 months prior to the study No prior EGFR inhibitors | USA: Denver CO, Ann Arbor MI. | University of Colorado Janssen | NCT05845671 | Amivantamab is a monoclonal antibody that is approved for the treatment of EGFR exon 20 insertion mutation after progession on platinum chemotherapy. It targets ERBB and cMET, resistance pathways in ALK and other cancers. Amivantamab will be added to the current TKI. | ||||||||||||||||||
38 | 12/23/2022 | CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC | 1/2 | Stage VI or recurrent ALK NSCLC Progression after targeted therapies No more than 6 prior lines of systemic therapies No prior PD-1 or PD-L1 inhibitor immunotherapies Brain mets okay if stable | USA: Tampa, FL - Moffitt Cancer Center | Moffitt Cancer Center | NCT05681780 | This is a therapy where cancer-attacking while blood cells are developed in a lab using each patients' resected tumor. A short course of chemotherapy depletes the white blood cells, then there is one infusion of the enhanced white blood cells. Nivolumab will be given before and after infusion. | ||||||||||||||||||
39 | 7/2022 | A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma (HARMONIC) | 2 | Inoperable advanced (stage III or IV) ALK adenocarcinoma Other targetable mutations included Never smoker Has exhausted TKIs Brain mets must be stable Prior radiation okay | USA: Goodyear AZ. Beverly Hills, Fountain Valley, Los Alamitos, Los angeles CA. Newman GA. Rolling Meadows, Zion IL. Morristown NJ. Patchogue NY,. Dallas TX, Fairfax VA. | Lantern Pharma | NCT05456256 | Never smokers with lung cancer will be given LP-300 with chemotherapy after exhauting TKIs.A subset of never smokers in another trial had improved survival with this combination. | ||||||||||||||||||
40 | 5/1/2022 | A Study of NVL-655 (new ALK TKI targeting ALK and resistance mutations) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) | 1/2 | Advanced or metastatic ALK lung cancer or solid tumor For NSCLC: progression after 1-3 lines of TKI treatment, including crizotinib, ceritinib, alectinib, brigatinib, or lorlatinib. For ALK soild tumors: at least one prior systemic anticancer therapy, or no satifactory standard therapy exists Measurable disease according to RECIST 1.1 | USA: Orange, Sacramento, Stanford CA, Denver CO, Miami FL, Boston MA, Detroit MI, Durham NC, NYNY, Columbus OH, Nashville TN, Houston TX, Seattle WA. Washington DC Canada: Edmonton,Toronto Australia: Saint Leonards, Melbourne, Woolloongabba Spain:A Coruna, Barcelona, Madrid UK: Manchester, Sutton Singapore | Nuvalent | NCT05384626 | NVL-655 is a new ALK inhibitor that targets resistance mutations, including compound mutations that can occur after lorlatinib treatment. | ||||||||||||||||||
41 | 7/8/2021 | SNK01 (Super Natural Killer Cells) in combination with gemcitabine chemotherapy and/or EGFR antibody in NSCLC who were failed by TKI treatment (SNK_ASTER) | 1/2 | Advanced NSCLC with at least one gene mutation (incl. ALK) Progression after at least one TKI Previous platinum chemotherapy okay Stable brain mets okay Must stop TKI 2 weeks before enrollment | Korea: Seoul | NKMAX Co, ltd | NCT04872634 | EGFR inhibitor is the monoclonal antibody cetuximab. It will be added to nautral killer cells and gemcitabine chemo in some patients. EGFR mutation does not determine who gets the EGFR antibody. | ||||||||||||||||||
42 | 12/1/2020 | Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, (TALACOM Trial) | 1 | Advanced/metastatic ALK NSCLC or selected other targetable mutations. Progression or intolerance of standard therapies Fresh or recent tumor sample No unstable brain mets or brain mets requiring steroids | USA: Houston (MD Anderson) | MD Anderson NCI | NCT04693468 | Talazparib and crizotinib will be given to all ALK patients. Talaoparib is a PARP inhibitor which stops cancer cells from repairing themselves. | ||||||||||||||||||
43 | ||||||||||||||||||||||||||
44 | 5/1/2020 | Lorlatinib Combinations in ALK Lung Cancer (Lorlatinib + Crizotinib / Lorlatinib + Binimetinib / Lorlatinib + TNO155 ) | 1/2 | Advanced ALK+ NSCLC Prior Chemo okay Progression on at least one ALK TKI Brain mets must be stable. LMD is included in trial. | USA: Boston: Massachsetts General, | Mass General Array Biopharma Pfizer | NCT04292119 | Assigned to either Lor/Criz or Lor/Binimetinib or Lor/TNO155 Unless biopsy shows MET, then receive Lor/Criz | ||||||||||||||||||
45 | 9/4/2019 | Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC | 2 | Advanced or metastatic ALK+ NSCLC Progression on at least one ALK inhibitor No more than 2 prior cycles of chemotherapy No untreated active brain mets | France: Angers, Annecy, Brest, Caen, Creteil, Grenoble, La Reunion, Limoges, Lyon, Marseilles, Orleans, Paris, Pessac, Pierre-Benite, Rennes, Rouen, Strasbourg, Toloun, Toulouse, Villenave-d"Ornon. More sites planned in France | Centre Francois Baclesse | NCT0402558 | Non-random addition of Bevacizumab to Carbo/Alimta/Tecentriq. Tecentriq is a checkpoint inhibitor immunotherapy. This class of drug is seldom effective in ALK. | ||||||||||||||||||
46 | Recruiting for Leptomeningeal Metastases | |||||||||||||||||||||||||
47 | 6/12/2021 | Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases (ReSPECT-LM) | 1 | Documented LMD; Type 1 and 2 of any primary tumor type. 2D LMD excluded No serious extrameningeal progression, or other serious illness No prior spinal cord radiation or whole brain radiation No current CNS-penetrant chemotherapy | USA: Chicago IL, Dallas, San Antonio TX. Site planned in Houston | Plus Therapeutics | NCT05034497 | Participants will be given a single dose of 186RNL (radionuclide clinical study drug) into the spinal fluid through a intraventricular catheter (Ommaya resevoir). | ||||||||||||||||||
48 | ||||||||||||||||||||||||||
49 | ||||||||||||||||||||||||||
50 | ||||||||||||||||||||||||||
51 | ||||||||||||||||||||||||||
52 | ||||||||||||||||||||||||||
53 | ||||||||||||||||||||||||||
54 | ||||||||||||||||||||||||||
55 | ||||||||||||||||||||||||||
56 | ||||||||||||||||||||||||||
57 | ||||||||||||||||||||||||||
58 | ||||||||||||||||||||||||||
59 | ||||||||||||||||||||||||||
60 | ||||||||||||||||||||||||||
61 | ||||||||||||||||||||||||||
62 | ||||||||||||||||||||||||||
63 | ||||||||||||||||||||||||||
64 | ||||||||||||||||||||||||||
65 | ||||||||||||||||||||||||||
66 | ||||||||||||||||||||||||||
67 | ||||||||||||||||||||||||||
68 | ||||||||||||||||||||||||||
69 | ||||||||||||||||||||||||||
70 | ||||||||||||||||||||||||||
71 | ||||||||||||||||||||||||||
72 | ||||||||||||||||||||||||||
73 | ||||||||||||||||||||||||||
74 | ||||||||||||||||||||||||||
75 | ||||||||||||||||||||||||||
76 | ||||||||||||||||||||||||||
77 | ||||||||||||||||||||||||||
78 | ||||||||||||||||||||||||||
79 | ||||||||||||||||||||||||||
80 | ||||||||||||||||||||||||||
81 | ||||||||||||||||||||||||||
82 | ||||||||||||||||||||||||||
83 | ||||||||||||||||||||||||||
84 | ||||||||||||||||||||||||||
85 | ||||||||||||||||||||||||||
86 | ||||||||||||||||||||||||||
87 | ||||||||||||||||||||||||||
88 | ||||||||||||||||||||||||||
89 | ||||||||||||||||||||||||||
90 | ||||||||||||||||||||||||||
91 | ||||||||||||||||||||||||||
92 | ||||||||||||||||||||||||||
93 | ||||||||||||||||||||||||||
94 | ||||||||||||||||||||||||||
95 | ||||||||||||||||||||||||||
96 | ||||||||||||||||||||||||||
97 | ||||||||||||||||||||||||||
98 | ||||||||||||||||||||||||||
99 | ||||||||||||||||||||||||||
100 | ||||||||||||||||||||||||||